This single-arm Phase II study investigating two cycles of atezolizumab achieved the primary efficacy endpoint, showing a pathological complete response rate of 31%.
Omics Core is the first FDA authorized custom-targeted, whole-exome sequencing platform to report both overall TMB in tumor specimens from 19,396 protein-coding genes (whole exome) and somatic alterations in 468 cancer-relevant genes.
The pilot project will provide information for 147 genes that are well-established indicators of increased risk for certain diseases for which clinical treatment guidelines are established.
As the use of genomic testing increases, many doctors are failing to discuss the costs of these tests with their patients, leaving them at risk of unexpected medical bills.
Through the acquisition, Invitae will gain access to Clear Genetics' chatbot named Gia, short for “Genetic Information Assistant,” which is designed to offer patients guidance for understanding test results.
Confera Dx is currently in development with the intention to be made available next year as a laboratory-developed test performed by Lexent in a CLIA-certified laboratory with the intention of developing a distributed in vitro diagnostic at a later date.
The collaboration will integrate Thermo Fisher’s Orbitrap gas chromatography mass spectrometry (GC-MS) instrumentation into Owlstone’s breath biopsy platform to conduct metabolomics studies for unique biomarkers.
The test stratifies patients based on their risk of subsequently experiencing a severe disease course, which is characterized by the requirement for multiple escalations in treatment due to frequently relapsing or chronically active disease.
Developers of pharmacogenetic tests cheered in August when United Healthcare (UHC) concluded in a policy statement effective October 1, that “the use of pharmacogenetic...
Single cell analysis, CRISPR, glycomics, and other advanced technologies are making it possible to finally uncover the root causes of autoimmune diseases and possibly...